The addition of Arikayce to guideline-based therapy (GBT) was superior to GBT alone in patients with refractory Mycobacterium avium complex (MAC) lung disease, according to data presented at ATS 2019.
The addition of Arikayce to guideline-based therapy (GBT) was superior to GBT alone in patients with refractory Mycobacterium avium complex (MAC) lung disease, according to data presented at ATS 2019.
Read More
Six months after Insmed Inc launched Arikayce for treatment of Mycobacterium avium complex (MAC) lung disease, the drug has netted $21 million in sales.
Read More
The US FDA has approved Arikayce for the treatment of lung disease caused by Mycobacterium avium complex, a type of nontuberculous mycobacteria commonly found in water and soil.
Read More
